Details for Patent: 7,767,675
✉ Email this page to a colleague
Which drugs does patent 7,767,675 protect, and when does it expire?
Patent 7,767,675 protects TABRECTA and is included in one NDA.
This patent has seventy-eight patent family members in thirty-six countries.
Summary for Patent: 7,767,675
| Title: | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| Abstract: | The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. |
| Inventor(s): | Zhuo; Jincong (Boothwyn, PA), Xu; Meizhong (Hockessin, DE), He; Chunhong (Boothwyn, PA), Zhang; Colin (Ambler, PA), Qian; Ding-Quan (Newark, DE), Metcalf; Brian (Moraga, CA), Yao; Wenqing (Kennett Square, PA) |
| Assignee: | Incyte Corporation (Wilmington, DE) |
| Application Number: | 11/942,130 |
|
Patent Claim Types: see list of patent claims | Use; Compound; |
Drugs Protected by US Patent 7,767,675
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,767,675
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2099447 | ⤷ Sign Up | C02099447/01 | Switzerland | ⤷ Sign Up |
| European Patent Office | 2099447 | ⤷ Sign Up | CA 2022 00053 | Denmark | ⤷ Sign Up |
| European Patent Office | 2099447 | ⤷ Sign Up | 301209 | Netherlands | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
